Profile data is unavailable for this security.
About the company
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.
- Revenue in USD (TTM)0.00
- Net income in USD-31.57m
- Incorporated2020
- Employees54.00
- LocationBetter Therapeutics Inc548 Market St. #49404SAN FRANCISCO 94101United StatesUSA
- Phone+1 (415) 887-2311
- Fax+1 (302) 655-5049
- Websitehttps://www.bettertx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baudax Bio Inc | 310.00k | -25.83m | 440.29k | 9.00 | -- | -- | -- | 1.42 | -17.25 | -9.17 | 0.0778 | -0.0985 | 0.0163 | -- | -- | 34,444.45 | -135.61 | -112.14 | -- | -192.87 | -1,445.81 | -- | -8,331.61 | -9,179.73 | -- | -- | 1.30 | -- | 17.50 | -- | -164.95 | -- | -56.52 | -- |
Meso Numismatics Inc | 2.41m | -9.81m | 449.78k | 1.00 | -- | -- | -- | 0.1866 | -0.7886 | -0.7886 | 0.1936 | -1.74 | 0.4398 | -- | 65.37 | -- | -179.09 | -192.08 | -- | -- | 69.53 | 60.24 | -407.21 | -821.49 | -- | -0.1103 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
NovAccess Global Inc | 0.00 | -1.74m | 526.31k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
Hanyuan Biotech International Inc | 10.65m | 3.14m | 539.39k | -- | 0.0294 | 0.0064 | 0.1481 | 0.0506 | 0.2246 | 0.2246 | 0.7611 | 1.03 | -- | -- | -- | -- | -- | -- | -- | -- | 68.54 | -- | 29.51 | -- | 13.36 | 25.66 | 0.00 | -- | 50.51 | -- | 106.71 | -- | -- | -- |
GlobeStar Therapeutics Corp | 0.00 | -1.98m | 581.46k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
Better Therapeutics Inc | 0.00 | -31.57m | 598.34k | 54.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | -0.2449 | 0.00 | -- | -- | 0.00 | -162.15 | -- | -378.28 | -- | -- | -- | -- | -- | -- | -15.18 | 3.27 | -- | -- | -- | 1.43 | -- | -- | -- |
Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 599.73k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
Emo Capital Corp | -100.00bn | -100.00bn | 639.85k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -0.0017 | -- | -- | -- | -- | -- | -7,495.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -138.44 | -- | -- | -- |
International Stem Cell Corp | 7.83m | -327.00k | 720.40k | 29.00 | -- | -- | -- | 0.092 | -0.0409 | -0.0409 | 0.9785 | 0.0045 | 1.46 | 2.53 | 11.87 | 270,069.00 | -5.81 | -29.22 | -68.13 | -73.82 | 58.58 | 59.49 | -3.97 | -21.01 | 0.4672 | -6.06 | 0.9898 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
Capstone Holding Corp | 0.00 | -358.00k | 728.95k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
Bellerophon Therapeutics Inc | 5.64m | -9.25m | 764.30k | 18.00 | -- | 0.2053 | -- | 0.1355 | -0.8353 | -0.8353 | 0.5054 | 0.3044 | 0.6414 | -- | -- | 313,333.30 | -105.23 | -55.57 | -165.94 | -77.33 | -- | -- | -164.06 | -- | -- | -- | 0.00 | -- | -- | -- | -11.69 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Capital Investment Advisory Services LLCas of 31 Mar 2024 | 71.00k | 0.13% |
XTX Markets LLCas of 31 Mar 2024 | 32.67k | 0.06% |
BlackRock Investment Management LLCas of 31 Dec 2023 | 1.11k | 0.00% |
Aspire Private Capital LLCas of 31 Mar 2024 | 200.00 | 0.00% |
G1 Execution Services LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Geode Capital Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
BofA Securities, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |
PSI Advisors LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Jane Street Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Corient Private Wealth LLCas of 31 Mar 2024 | 0.00 | 0.00% |